LETTER TO THE EDITOR

Eight-Year Long-Term Survival of an Advanced Gastric Cancer Patient Treated by Multidisciplinary Therapy Including Repeated Surgery and Metronomic Chemotherapy

Takahisa Fujikawa, Yasunori Yoshimoto, Akira Tanaka

A 69-year-old male, who had gastric cancer with extensive intra-abdominal lymph node metastasis, received palliative distal gastrectomy. He underwent repeated resection of metachronous right and left adrenal metastatic lesions 2 years and 5.3 years after the initial operation, respectively. The patient also experienced right femoral bone metastasis and IVC tumour thrombus 2.9 years and 6.6 years after the initial surgery, which were treated by radiation therapy. The slowly progressive tumour status was maintained by continuation of metronomic chemotherapy including S-1 as a key drug, and a total of 8-year long-term survival was achieved. Although rare, some selected patients with advanced gastric cancer have a chance of long-term survival, like the current case. The efficacy of multidisciplinary therapy for far advanced gastric cancer patients, especially an important role of repeated surgery and metronomic chemotherapy, was discussed.

Key words: Advanced gastric cancer; Distant metastasis; Long-term survival; Multidisciplinary therapy; Repeated surgery; Metronomic chemotherapy

© 2017 The Author(s). Published by ACT Publishing Group Ltd. All rights reserved.

Figure 1 (A) Enhanced CT scan of the abdomen revealed severely thick wall of the stomach (arrows) with extensive regional lymph node swelling (arrow heads). (B) Gross specimen of the resected distal stomach showed irregular wall thickness involving the antrum. (C) MR images 2.9 years after the initial operation showed right femoral bone metastasis (arrows), which was treated by radiation therapy. (D) Enhanced CT scan 6.6 years after the initial operation revealed tumour thrombus in the inferior vena cava and left renal vein (arrows).

Figure 2 The whole clinical course of the current patient with serial changes in serum CEA values. Abbreviations: CDDP: cisplatin; PTX: paclitaxel; CPT-11: irinotecan; Tx: therapy; LNs: lymph nodes; Rt: right; Lt: left; IVC: inferior vena cava; meta.: metastasis.
was developed 5.3 years after the initial operation, and again surgically resected. Because the patient’s performance status was deteriorated postoperatively, metronomic chemotherapy consisting of bi-daily administration of 60% dose of S-1 was started, and monthly administration of 80% dose of irinotecan was later added. The disease status was slowly progressive but stable without any symptom, when the left scapula metastasis and IVC tumour thrombus were obvious 6.6 years after the initial operation (Figure 1D). Both metastatic lesions were treated by radiation therapy combined with hyperthermia, and partial response was achieved. Slowly progressive tumour status was maintained for additional one year by continuation of metronomic S-1/irinotecan chemotherapy. The patient’s performance status was deteriorated due to pneumonia and sepsis 7.2 years after the initial operation, and only metronomic S-1 monotherapy was continued thereafter. Finally, brain metastasis and intractable pleural empyema developed 7.6 years after the initial operation, resulting in discontinuation of chemotherapy, and the patient expired 8 years after the initial operation (Figure 2).

Gastric cancer is the fourth most commonly diagnosed cancer and the second most common cause of cancer-related death worldwide, and most patients present with advanced and/or metastatic diseases except in East Asia[1]. The effect of resecting metastatic tumours from gastric cancer is limited because metastasis from gastric cancer is considered to present as multiple recurrence or peritoneal dissemination[2]. Some selected patients with advanced and metastatic gastric cancer may have a chance of long-term survival thanks to recent advances in multimodal therapy including surgery, radiation therapy and chemotherapy[3], although an 8-year long-term survival case of far advanced gastric cancer, like the current case, is extremely rare. In our case, maintenance of modulated metronomic chemotherapy and the timing of repeated surgery and radiation therapy were of paramount importance to achieve long-term survival with favourable quality of life. The metronomic chemotherapy, defined as frequent or continuous administration of conventional cytotoxic drug in comparatively low doses over extended periods with no prolonged breaks, has the potential benefit not only by achieving significantly reduced toxicity compared to maximum tolerated chemotherapy, but also by keeping stable tumour status via optimisation of the antiangiogenic properties of cytotoxic drugs[4-6]. In advanced or metastatic gastric cancer patients with relatively poor performance status, the use of oral fluoropyrimidines as metronomic chemotherapy, such as S-1, capecitabine or UFT, seems to be potentially beneficial[6]. In the current case, metronomic chemotherapy using S-1 as a key drug could offer an over 5-year long-term survival, as well as a favourable quality of life without any severe symptoms.

REFERENCES


Peer reviewer: Fethi Derbel